ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

CAMP4 Therapeutics partners with Alnylam on finding new liver disease drug targets

by Ryan Cross
January 27, 2019 | APPEARED IN VOLUME 97, ISSUE 4

Alnylam Pharmaceuticals, a developer of RNA interference (RNAi) therapies, is partnering with CAMP4 Therapeutics to find new drug targets for a rare liver disease. CAMP4, which announced raising $30 million in series A financing in May 2018, uses computational tools to understand the rules dictating how genes are regulated—turned up or down—in cell types across the body. Because Alnylam’s RNAi drugs work by effectively turning genes down, the partnership may provide the first big test of CAMP4’s technology.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment